Mineralys Therapeutics Inc. (NASDAQ:MLYS) is one of the 8 Hidden Multibagger Stocks to Buy Now.
During the last few trading sessions, Mineralys Therapeutics Inc. (NASDAQ:MLYS) has seen positive momentum
On June 4, Goldman Sachs analyst Richard Law reiterated a Buy rating on the stock and assigned a target price of $42. Earlier on June 2, MLYS revised its agreement with Tanabe Pharma to gain full worldwide rights to lorundrostat without having to pay future royalties. Under this amendment, the company agreed to pay Tanabe a $200 million upfront cash payment and could make additional payments of up to $365 million if certain commercial targets are achieved.
Moreover, the company secured a loan of up to $500 million from funds managed by Pharmakon Advisors. The financing will be provided in stages, with access to additional funds tied to the FDA approval of lorundrostat and the achievement of certain sales milestones. This loan will provide capital to support the company’s growth and commercialization plans.